Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name PDGFRA Y288C
Gene Variant Detail

PDGFRA Y288C (gain of function - predicted)

Relevant Treatment Approaches PDGFR Inhibitor (Pan) PDGFR-alpha Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
PDGFRA Y288C Advanced Solid Tumor resistant PDGFR Inhibitor (Pan) Crenolanib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Crenolanib in culture (PMID: 30389923). 30389923
PDGFRA Y288C Advanced Solid Tumor resistant PDGFR Inhibitor (Pan) Nilotinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 30389923). 30389923
PDGFRA Y288C Advanced Solid Tumor resistant PDGFR Inhibitor (Pan) Sunitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Sutent (sunitinib) in culture (PMID: 30389923). 30389923
PDGFRA Y288C Advanced Solid Tumor no benefit AZD9150 Preclinical - Cell culture Actionable In a preclinical study, ISIS-STAT3rx (AZD9150) did not decrease viability of transformed cells expressing PDGFRA Y288C in culture (PMID: 30389923). 30389923
PDGFRA Y288C Advanced Solid Tumor resistant PDGFR Inhibitor (Pan) Imatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Gleevec (imatinib) in culture (PMID: 30389923). 30389923
PDGFRA Y288C Advanced Solid Tumor sensitive Trametinib Preclinical - Cell culture Actionable In a preclinical study, Mekinist (trametinib) treatment resulted in decreased proliferation of transformed cells expressing PDGFRA Y288C in culture (PMID: 30389923). 30389923
PDGFRA Y288C Advanced Solid Tumor sensitive GSK2126458 Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated sensitivity to GSK2126458 (omipalisib) in culture, resulting in decreased cell proliferation (PMID: 30389923). 30389923
Clinical Trial Phase Therapies Title Recruitment Status